ENBI

Entheon Biomedical Corp.

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. ("Divergence"), a compan... Read More...

KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021

Featuring presentations by eminent psychedelics companies and industry leaders including keynote speakers, Rick Doblin, MAPS and Amy Emerson, MAPS Public Benefit CorporationNEW YORK, Jan. 11, 2021 -- KCSA Strategic Communications, an integrated strategic communications firm specializing in public relations, investor relations and social m... Read More...

Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor.In his role, Mr. ... Read More...

Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Hea... Read More...

Entheon Biomedical Announces Private Placement

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) - Β Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200... Read More...

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). ... Read More...

Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team ... Read More...

Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021

Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Cen... Read More...